Summary
An 18-year-old female patient receiving adjuvant chemotherapy for osteogenic sarcoma developed a pruritic erythematous rash during infusion of the eighth dose of methotrexate (8 g/m2) in the series. In other respects, the infusion proceeded normally but the 24-hour serum concentration of methotrexate was unexpectedly and extremely high, 574 /μmol/L. Dosing error was excluded, as was the hypothesis that the high concentrations were due to the presence of methotrexate-specific antibodies. Acute oliguria and renal failure were the primary manifestations of the drug-induced toxicity and the high concentrations can be attributed to decreased renal elimination of the drug over the first 24 hours. Treatment consisted of folinic acid rescue, forced diuresis, sequential charcoal haemoperfusion and haemodialysis, and repeated oral doses of activated charcoal. After examination of the contribution of the extracorporeal procedures and the charcoal to the elimination of the drug, the relative lack of morbidity was attributed primarily to the folinic acid rescue and the intensive supportive care.
Similar content being viewed by others
References
Abelson HT, Fosburg MT, Beardsly GP, Goorin AM, Gorka C, et al. Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine. Journal of Clinical Oncology 1: 208–216, 1983
Aherne GW, Piall E, Marks V, Mould G, White WF. Prolongation and enhancement of serum methotrexate concentrations by probenecid. British Medical Journal 1: 1097–1099, 1978
Bleyer, WA. The clinical pharmacology of methotrexate: new applications of an old drug. Cancer 41: 36–51, 1978
Breithaupt H, Kuenzlen E. Pharmacokinetics of methotrexate and 7-hydroxymethotrexate following infusions of high-dose methotrexate. Cancer Treatment Reports 66: 1733–1741, 1982
Chan H, Evans WE, Pratt CB. Recovery from toxicity associated with high-dose methotrexate: prognostic factors. Cancer Treatment Reports 61: 797–804, 1977
Christophidis N, Louis WJ, Lucas I, Moon W, Vajda FJE. Renal clearance of methotrexate in man during high-dose oral and intravenous infusion therapy. Cancer Chemotherapy and Pharmacology 6: 59–64, 1981
Coassolo P, Valentin M, Bourdeaux M, Briand C. Modification of human serum albumin binding of methotrexate by folinic acid and certain drugs used in cancer chemotherapy. European Journal of Clinical Pharmacology 17: 123–129, 1980
Condit PT, Chanes RE, Joel W. Renal toxicity of methotrexate. Cancer 23: 126–131, 1969
Da Costa M, Isacoff W, Rothenberg SP, Iqbal MP. Protein-methotrexate-IgG complexes in the serum of patients receiving high-dose antifolate therapy. Cancer 46: 471–474, 1980
Erttmann R, Landbeck G. Effect of oral cholestyramine on the elimination of high-dose methotrexate. Journal of Cancer Research and Clinical Oncology 110: 48–50, 1985
Ey PL, Prowse SJ, Jenkin CR. Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum. Immunochemistry 15: 429–435, 1978
Freeman-Narrod M, Kim JS, Ohanissian H, Mills K, Smiley JW, et al. The effect of high-dose methotrexate on renal tubules as indicated by urinary lysozyme concentration. Cancer 50: 2775–2779, 1982
Gadgil SD, Damle SR, Advane SH, Vaidya AB. Effect of activated charcoal on the pharmacokinetics of high-dose methotrexate. Cancer Treatment Reports 66: 1169–1171, 1982
Gibson TP, Reich SD, Krumlovsky FA, Ivanovich P. Hemoper-fusion for methotrexate removal. Clinical Pharmacology Therapeutics 23: 351–355, 1978
Goldberg NH, Romolo JL, Austin EH, Drake J, Rosenberg SA. Anaphylactoid type reactions in two patients receiving high dose intravenous methotrexate. Cancer 14: 52–55, 1978
Molina R, Fabian C, Cowley B. Use of charcoal hemoperfusion with sequential hemodialysis to reduce serum methotrexate levels in a patient with acute renal insufficiency. American Journal of Medicine 82: 350–352, 1987
Nixon PF. Folinic acid: pharmacokinetics and pharmacodyn-amics. Clinical and Experimental Pharmacology and Physiology 5 (Suppl.): 35–41, 1979
Paxton JW. The protein binding and elimination of methotrexate after intravenous infusions in cancer patients. Clinical and Experimental Pharmacology and Physiology 9: 225–234, 1982
Pitman SW, Parker LM, Tattersall MHN, Jaffe N, Frei E. Clinical trial of high-dose methotrexate (NSC-740) with citrovorum factor (NSC-3590) — toxicologie and therapeutic observations. Cancer Chemotherapy Reports 6: 43–49, 1975
Pond SM. Role of repeated oral doses of activated charcoal in clinical toxicology. Medical Toxicology 1: 3–11, 1986
Smith TW, Lloyd BL, Spicer N, Haber E. Immunogenicity and kinetics of distribution and elimination of sheep digoxin-specific IgG and Fab fragments in the rabbit and baboon. Clinical and Experimental Immunology 36: 384–396, 1979
Shen DD, Azarnoff DL. Clinical pharmacokinetics of methotrexate. Clinical Pharmacokinetics 3: 1–13, 1978
Von Hoff DD, Penta JS, Helman LJ, Slavik M. Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration. Cancer Treatment Reports 61: 745–748, 1977
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Grimes, D.J., Bowles, M.R., Buttsworth, J.A. et al. Survival After Unexpected High Serum Methotrexate Concentrations in a Patient with Osteogenic Sarcoma. Drug-Safety 5, 447–454 (1990). https://doi.org/10.2165/00002018-199005060-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-199005060-00005